Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
Status:
Completed
Trial end date:
2020-05-12
Target enrollment:
Participant gender:
Summary
This study evaluates PERSERIS at a higher dose than what has been administered in previous
clinical trials. Subjects with stable schizophrenia on a dose of 5-6 mg oral risperidone will
be switched to PERSERIS at the higher dose, which is believed to be similar to the oral dose